A Review of the Current and Future Position for Johnson & Johnson in the Pharmaceutical Industry, Including a 1-6 Year Sales Forecasts

Business Wire, Nov 10, 2005

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c27462) has announced the addition of Pharmavitae 2005: Johnson & Johnson Global Analysis to their offering.

This Analysis examines the current position and future outlook for J&J in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

Understand how J&Js mature product portfolio and the risk of generic competition will impact sales growth over the forecast period

Benchmark J&Js performance against key rivals in the ethical pharmaceutical sector

Learn why J&J must continue to focus on M&A and licensing to generate sales growth over the forecast period

Topics Covered

Addendum:

CHAPTER 1 EXECUTIVE SUMMARY 5

Key findings

Current positioning: competitive outlook 2004

Future performance: growth drivers and resistors 2005-10

Evolution in therapeutic focus: 2004-10

Key issues facing J&J: 2005 - 10

Strategic outlook

CHAPTER 2 GLOBAL COMPANY STRATEGY

Introduction to Johnson & Johnson

Assessment of strategic position

Strengths

Weaknesses

Opportunities

Threats

Therapeutic foci

R&D productivity

Development opportunities

Organic growth

Partnerships/licensing

Mergers and acquisitions

Geographical expansion

Implications of financial position

CHAPTER 3 GLOBAL PORTFOLIO AND PIPELINE ANALYSIS

Therapy area focus in 2004

Business development by therapy area

Forecast revenue stream, 2005-10

Therapy area forecasts to 2010

CNS franchise

Marketed products

R&D compounds

CNS portfolio sales forecasts and forecast revenue growth

Oncology franchise

Marketed products

R&D compounds

Oncology portfolio sales forecasts and forecast revenue growth

Arthritis, immune & inflammatory franchise

Marketed products

R&D compounds

AIID portfolio sales forecasts and forecast revenue growth

Gastrointestinal franchise

Marketed products

R&D compounds

Gastrointestinal portfolio sales forecasts and forecast revenue growth

Women's health franchise

Marketed products

R&D compounds

Women's health portfolio sales forecasts and forecast revenue growth

Infectious disease franchise

Marketed products

R&D compounds

Infectious disease portfolio sales forecasts and forecast revenue growth

HIV franchise

Marketed products

R&D compounds

HIV portfolio sales forecasts and forecast revenue growth

Other products

Marketed products

R&D compounds

Other products sales forecasts and forecast revenue growth

CHAPTER 4 CORPORATE DEVELOPMENT

Financial position, 2003 - 2004

Profitability, 2000-2004

Revenue growth

Cost structure

Profitability

Liquidity, 2000-2004

2004 performance benchmarking

Business model clustering according to 2004 cost ratios

2003 growth and investment momentum

Key events shaping corporate activity, 2000-2004

Merger and acquisition activity

Corporate alliances and deals

CHAPTER 5 APPENDIX : SUPPORTING DATA

Financial data

Exchange rates

Biogeneric threat

Methodology for therapy area forecasting

LIST OF TABLES

LIST OF FIGURES

For more information visit http://www.researchandmarkets.com/reports/c27462